Latest news

NEW YORK and PARIS, September 9th, 2025 (GLOBE NEWSWIRE) – Rarecells, a pioneer in liquid biopsy technologies, today presented new data (poster EP.06.64) at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain, from its BioMolCTC Trial conducted in collaboration with Prof. Filippo Lococo’s team at Policlinico Gemelli in Rome. Circulating Tumor Cells (CTCs) are well-established, non-invasive cancer markers, but clinical use of CTC-DNA assays has been limited by sensitivity, scalability, and practicality issues. This study presents the first clinical application of Rarecells’ next-generation ISET® technology, redesigned

Oncologist Patrizia Paterlini: «I look for tumor cells before the tumor becomes visible, which is why I patented a test that looks for tumor cells in the blood in the very early stages of development»   “I chose research because, as an oncologist, I saw too many patients die—I felt powerless,” says the researcher who patented a method to search for cancer cells in the blood at the very earliest stages of the disease. By Veronica Bianchini (translated from Italian: https://www.vanityfair.it/article/loncologa-patrizia-paterlini-brechot-cerco-le-cellule-tumorali-prima-che-siano-visibili-per-questo-ho-brevettato-un-test-che-le-cerca-nel-sangue-nelle-primissime-fasi-di-sviluppo) June 24, 2025 “I chose research because, as an

NEW YORK, NY and PARIS, FRANCE – June 18, 2025 Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership experience across private industry and academia. She has a distinguished track record of building high-performing teams, developing innovative diagnostic tests, establishing world-class laboratory environments, and advancing critical research in cancer biology, genomics, and epigenetics. Dr. Shaknovich currently serves as Chief Medical Officer at Agilent Technologies, where she oversees medical